Accession Number:

ADA383054

Title:

Insulin Like Growth Factor I Receptor Function in Estrogen Receptor Negative Breast Cancer

Descriptive Note:

Annual rept.1 Jul 1999-30 Jun 2000

Corporate Author:

GEORGETOWN UNIV WASHINGTON DC MEDICAL CENTER

Personal Author(s):

• Dougherty, Michele

Report Date:

2000-07-01

Pagination or Media Count:

14.0

Abstract:

A recent CALGB 9344 trial INT 048 examined the addition of paclitaxel therapy to standard chemotherapy regimes. The results of this trial demonstrated addition of paclitaxel to standard adjuvant therapy, doxorubicin and cyclophosphamide, was associated with proportional reductions in both relapse risk and risk of death. Subgroup analyses were conducted to identify tumor characteristics that would predict response to paclitaxel treatment. These analyses showed that the benefit of paclitaxel treatment was restricted to ER- patients CALGB central statistics office, indicating that there was an association between estrogen receptor status and paclitaxel sensitivity. The results reported here demonstrate that the differences in growth between ER and ER- breast cancer cells reflect the differential sensitivity to paclitaxel observed both in vitro and in the clinic.

Descriptors:

• *IN VITRO ANALYSIS
• *RECEPTOR SITES(PHYSIOLOGY)
• *CHEMOTHERAPY
• *INSULIN
• *INJECTIONS(MEDICINE)
• *CYCLOPHOSPHAMIDE
• *ESTROGENS
• *BREAST CANCER
• RISK
• STATISTICS
• NEOPLASMS
• SENSITIVITY
• REDUCTION
• THERAPY
• DEATH
• SENSE ORGANS
• GROWTH(PHYSIOLOGY)
• DIFFERENTIAL CROSS SECTIONS

Subject Categories:

• Anatomy and Physiology
• Medicine and Medical Research
• Pharmacology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE